Open session of the standing technical committee of the EUFMD- 2004

Page 33

consideration of “substances from animals for which there is a low probability that infectious substances are present, or where the concentration is at the level naturally encountered, not to be subject to these Regulations (2.6.3.2.3.2)” since these samples do not represent a risk to transport workers or to the environment. Conclusion 1. The meeting endorsed and supported the actions taken by EUFMD /FAO and OIE on these subjects. Recommendations 1. 2. 3.

The actions taken by OIE to guarantee a realistic possibility for transport of samples should be supported. Laboratories should improve their collaboration and information exchange, which will support global FMD control. Close collaboration between the EUFMD Research Group and the OIE experts is essential for a coordinated improvement of the international standards.

Item 11 - Persistent and subclinical infections – Diagnostic and surveillance issues Drs. Paul Sutmoller and John Bashiruddin discussed vaccinated carriers and recovered carriers, respectively. An account of the actual risks compared to the perceived risks of FMD carriage by vaccinated carriers was discussed by Dr Sutmoller and co-authors, who considered that based on historical data, the risk of transmission of FMDV from carriers after emergency vaccination is smaller than the risk of introduction of FMDV by illegally imported meat (Appendix 63). Further it was suggested that the risk of transmission of FMDV from carriers might be of the same magnitude as the risk of import of meat from animal populations in countries using vaccination against FMD. Dr Bashiruddin from experimental evidence concluded that there were differences in the rate of carriage and clinical presentation dependent on the age of the cattle at the time of infection (Appendix 64). Drs. Franco De Simone and Kris De Clercq reported on the results of the validation exercise, undertaken as part of the EU ImproCon project, for various NSP-ELISA kit tests on sera from naïve, FMDV vaccinated, infected and vaccinated plus infected populations of cattle, sheep and swine (Appendix 6). Extensive analyses were shown and the workshop results were considered to have produced sufficient information to enable test comparison. However, they considered further analysis is needed before publication of the final report. Dr. Kitman Dyrting reported on the NSP-ELISA evaluation that is part of the Coordination Action of the IAEA/FAO, on pig sera from Hong Kong (Appendix 65). The sensitivity of NSP ELISA systems applied to the detection of exposed animals after outbreaks in pigs was reported to decrease with time subsequent to outbreaks. Dr. Nesya Goris considered the validation and batch-to-batch consistency of commercial diagnostic kits and their testing to ensure consistency of test results (Appendix 66). Conclusions 1. Experimental infection with the FMDV type O virus responsible for the outbreak in 2001 in the UK resulted in more carrier cattle in older than in younger cattle. 2. High specificities (CI lowest test, highest test system-prelim) with the current NSP ELISA systems were obtained in both unvaccinated and vaccinated, non-infected cattle. 3. The finding that samples from naive animals that scored false positive in one NSP tests often scored correctly in the other NSP tests may provide a basis for use of confirmatory tests to increase specificity. 4. Where there is no relevant national system, batch-to-batch testing is necessary when using diagnostic kits to ensure consistency of results; this could be organised internationally. Recommendations 1. Science-based risk assessments should be made to compare the risk associated with persistent infections, and risks associated with different eradication methods of FMD and trade in animals and animal products. 2. The ability and likelihood of FMD carrier bulls to transmit disease by the sexual route should be investigated.

24


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 82

17min
pages 492-500

Appendix 77

22min
pages 468-476

Appendix 78

25min
pages 477-484

Appendix 79

14min
pages 485-489

Appendix 81

1min
page 491

Appendix 80

1min
page 490

Appendix 76

12min
pages 464-467

Appendix 75

1min
page 463

Appendix 64

10min
pages 412-414

Appendix 72

13min
pages 455-460

Appendix 73

1min
page 461

Appendix 65

1min
page 415

Appendix 67

1min
page 424

Appendix 63

34min
pages 401-411

Appendix 62

2min
page 400

Appendix 54

8min
pages 361-363

Appendix 61

15min
pages 394-399

Appendix 55

11min
pages 364-366

Appendix 59

1min
page 385

Appendix 60

20min
pages 386-393

Appendix 56

1min
page 367

Appendix 42

21min
pages 270-276

Appendix 52

10min
pages 350-352

Appendix 50

21min
pages 330-339

Appendix 46

2min
page 307

Appendix 37

7min
pages 241-243

Appendix 38

7min
pages 244-246

Appendix 41

2min
page 269

Appendix 40

15min
pages 255-268

Appendix 36

16min
pages 236-240

Appendix 35

15min
pages 231-235

Appendix 34

25min
pages 224-230

Appendix 28

2min
page 198

Appendix 31

10min
pages 212-215

Appendix 29

16min
pages 199-203

Appendix 33

3min
pages 221-223

Appendix 27

1min
page 197

Appendix 26

27min
pages 188-196

Appendix 25

12min
pages 182-187

Appendix 23

8min
pages 168-171

Appendix 22

28min
pages 158-167

Appendix 15

2min
page 113

Appendix 16

7min
pages 114-116

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min
pages 144-145

Appendix 19

18min
pages 136-143

Appendix 14

4min
page 112

Appendix 13

10min
pages 107-111

Appendix 5

2min
page 64

Appendix 12

9min
pages 104-106

Appendix 3

9min
pages 47-49

Appendix 4

26min
pages 50-63

Appendix 8

12min
pages 77-80

Appendix 2

8min
pages 43-46

Open Session

6min
pages 39-42

Closed Session

2min
pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min
page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min
page 36

Item 14 – Regulatory compliance

2min
page 35

Item 10 – International issues

3min
page 32

Item 9 – Novel vaccines

3min
page 31

Item 7 – Optimisation of conventional vaccines

3min
page 29

Item 4 – Managing diagnostic demands

3min
page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min
page 30

Item 3 – Transmission and its control

3min
page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min
page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min
page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min
page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min
page 20
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.